Need help? Our team of experienced experts is here for you with full support.
AKA-283
Salicylic Acid
Cat. No.
AKA-283
CAS No.
69-72-7
MF
C7H6O3
MW
138.1207
Salicylic acid is a potent inhibitor of COX-2 activity at concentrations well below those required to inhibit NF-κB activation.
Advanced Equipments & Extensive Production Expertise
Commercial Manufacturing
Stable Quality
Customization Supporting
Technical Data
Description
Documents
Storage and Shipping
References
Product Name
Salicylic Acid
CAS No.
69-72-7
MF
C7H6O3
MW
138.1207
Specification
98%
Research Area
Intermediate
Disclaimer
This product is intended solely for scientific research or regulatory filing purposes. We do not provide products or services to individuals, please strictly comply with all applicable laws, regulations, and the committed use. Use for any other purpose is strictly prohibited.
Description
Salicylic acid is a potent inhibitor of COX-2 activity at concentrations well below those required to inhibit NF-κB activation. Packing: 1kg/bag; 25kg/drum or as request Availability: In Stock
Documents
Can't find the right version? Our team of experienced experts is here for you with full support.Contact Us
Storage and Shipping
Store in a cool & dry place, keep away from strong light and heat.
References
[1]. Mitchell JA, et al. Sodium salicylate inhibits cyclo-oxygenase-2 activity independently of transcription factor (nuclear factor kappaB) activation: role of arachidonic acid. Molecular Pharmacology. 1997 Jun;51(6):907-12.
[2]. Nixon M, et al. Salicylate downregulates 11β-HSD1 expression in adipose tissue in obese mice and in humans, mediating insulin sensitization. Diabetes. 2012 Apr;61(4):790-6.
[3]. Kang YS, et al. Acidic drug transport in vivo through the blood-brain barrier. A role of the transport carrier for monocarboxylic acids. Journal of Pharmacobio-dynamics. 1990 Feb;13(2):158-63.
Related Products
* Some statements have not been evaluated by national authorities. * Some products are not intended to diagnose, treat, cure, or prevent any disease. * For literature supporting, please contact us directly.